SPHN Webinar: A Translational Platform for New Theragnostics

About this Webinar:

Functional imaging of biological and pathological processes at a molecular level using positron emission tomography (PET) offers an unparalleled opportunity for personalized medicine in the future. With this Technology Transfer Project (TTP) we improve the availability of radionuclides and radiotracers for clinical studies we have established and improved the radiopharmacy platform to facilitate the production of innovative radiotracers according to Good Manufacturing Practice (GMP) for clinical studies. As part of the improvement, we installed automated radiosyntheses modules at the Paul Scherrer Institute as well a solid target station at the 18 MeV medical cyclotron of the ETH Hönggerberg.

Till today the TTP has produced the radiotracers: i) [18F]-AV1451 (to detect Tau-pathy in Alzheimer's patient) for ongoing clinical studies at the USZ, HUG and CHUV; ii) [18F]-AzaFol (targeting the folate receptor on tumor cells) for a multi-center, first-in-man study at the USZ, CHUV and the Cantonal Hospital St. Gallen; iii) [18F]-PSS-232 (targeting the mGluR5) for a clinical study investigating glutamate release after N-acetylcystein challenge and; iv) [177Lu]-PP-F11N a optimized minigastrin analog against the cholecystokinin receptor 2 expressed on medullary thyroid cancer. Overall more than half a dozen clinical studies were enabled and facilitated with the support since the start of the TTP within the PHRT initiative. We will present selected examples of the translational research activities from-bench-to bedside.